Welcome to our dedicated page for Dignitana news (Ticker: DIZTF), a resource for investors and traders seeking the latest updates and insights on Dignitana stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dignitana's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dignitana's position in the market.
Dignitana announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has reassigned payment for scalp cooling therapy under CPT code 0662T to New Technology APC 1520, effective January 1, 2022, with a national average payment of $1,850.50. CEO William Cronin highlighted this decision as a significant milestone for cancer patients, enhancing access to scalp cooling therapy. The reassignment aims to boost reimbursement efforts and utilization of DigniCap at medical facilities. Previously, reimbursement was significantly lower, with a proposed payment of only $34.72.
FAQ
What is the market cap of Dignitana (DIZTF)?
